Annual Report

Overview

The report presents Proteomics International's 2022 progress in commercialising PromarkerD, including production capacity for more than 50,000 tests, expansion into Britain, and regulatory steps in Australia and the United States. It also highlights completed or advancing validation work for endometriosis, airway disease and oesophageal cancer diagnostics. The company reports a gender-balanced workforce, with women comprising 59% of staff and 20% of the Board. Consolidated revenue from continuing operations was $3,436,458.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2022
Period: Ends 30 June 2022
Publication date: 30 August 2022
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services